Kamada Ltd KMDA 深 沪
等待开盘 03-26 09:30:00 美东时间
8.20
0.000
0.00%
华盛通- 最 高8.26
- 今 开8.22
- 成交量 3.64万股
- 最 低 8.15
- 昨 收 8.20
- 总市值 4.73亿
- 52周最高 9.10
- 市盈率 静 23.69
- 换手率 0.00%
- 52周最低 5.29
- 委 比 -56.33%
- 总股本 5768.61万
- 历史最高 17.50
- 量 比 0.38
- 振 幅 1.34%
- 历史最低 2.57
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million.
03-11 19:04
Kamada Q4 EPS $0.06 Misses $0.08 Estimate, Sales $44.678M Miss $45.422M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 22.08 percent. This is a 14.29 percent decrease over earnings of $0.07 per share from the same
03-11 19:03
What's Next: Kamada's Earnings Preview
Kamada (NASDAQ:KMDA) is gearing up to announce its quarterly earnings on Wednes...
03-11 00:01
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Kamada Ltd. will release its fourth quarter and fiscal year 2025 financial results on March 11, 2026, followed by an investment community conference call at 8:30am ET. The call will discuss the results and answer questions. Participants can join via phone or webcast. Kamada is a global biopharmaceutical company specializing in rare and serious conditions, with a focus on specialty plasma-derived therapies.
03-04 12:00
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to Entyvio (vedolizumab). The AVT80-GL-P01 study met all primary endpoints, demonstrating PK similarity, safety, tolerability, and immunogenicity profiles in healthy adult participants. This milestone supports the development and regulatory submissions of AVT16 and AVT80, biosimilar candidates for Entyvio.
02-05 08:00
Kamada forecasts double-digit profitable growth in 2026
Kamada forecasts 2026 revenues of $200M – $205M, compared to estimates of 200.7M and adjusted EBITDA of $50M –$53M. The 2026 outlook implies year-over-year growth of 13% in revenues and 23% in adjuste...
01-08 00:49
Kamada Sees FY2026 Sales $200.000M-$205.000M vs $200.598M Est
Kamada (NASDAQ:KMDA) sees FY2026 sales of $200.000 million-$205.000 million vs $200.598 million analyst estimate.
01-07 20:21
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $181.137M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $181.137 million estimate.
01-07 20:21
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. forecasts 2026 revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting 13% and 23% increases respectively from 2025 mid-point guidance. Growth is driven by organic expansion of its commercial product portfolio, including U.S. sales and ex-U.S. sales of key products like KAMRAB® and GLASSIA®. The company also prioritizes M&A and business development to enhance its product portfolio and long-term growth. Kamada ...
01-07 12:00
